3'-(iso-Propyl)-2',4'-dihydroxyacetophenone | 118604-45-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3'-(iso-Propyl)-2',4'-dihydroxyacetophenone
• 英文别名: 1-(2,4-Dihydroxy-3-propan-2-ylphenyl)ethanone
• CAS: 118604-45-8
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: BAZIJDCDORCIPU-UHFFFAOYSA-N

物化性质

• 沸点：
  352.9±12.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3'-(iso-Propyl)-2',4'-dihydroxyacetophenone 在 盐酸 、 铁粉 、 potassium carbonate 、 caesium carbonate 作用下， 以 乙醇 为溶剂， 反应 15.5h， 生成 1-[4-[(3-aminophenyl)methoxy]-2-hydroxy-3-propylphenyl]ethanone
  参考文献：
  名称：

  Synthesis and antiallergic activity of a novel series of 5-lipoxygenase inhibitors

  摘要：

  A series of novel substituted [[(phenoxymethyl)phenyl]amino]oxoalkanoic acid esters have been synthesized. These compounds were tested in vitro for their ability to inhibit the synthesis of 5-hydroxyeicosatetraenoic acid and leukotriene (LT) B4 from rat polymorphonuclear leukocytes (PMN) and in vivo as inhibitors ovalbumin- (OA) and LTD4-induced bronchospasm in the guinea pig. Compounds 5-12 and 25 had IC50's between 1 and 5.6 microM in the rat PMN 5-lipoxygenase assay. Compounds 1, 3, and 16 inhibited OA-induced bronchoconstriction (61%, 64%, and 57%, respectively), but only 1 showed activity against LTD4-induced bronchoconstriction. When tested against LTD4-induced contraction of isolated guinea pig tracheal spiral strips, 1 was a competitive inhibitor with a pKB of 4.94.

  DOI：

  10.1021/jm00161a031

文献信息

• Leukotriene B4 antagonists
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0327306A2

  公开（公告）日：1989-08-09

  The use of compound of structure wherein m is 1 or 2; n is 1, 2 or 3; p is 0, 1, or 2; R′ is hydrogen or methyl; R is phenyl substituted with A, R₁ and R₂ wherein R₁ and R₂ are independently selected from either 1) (S)a-(CH₂)b-(T)c-B wherein a is 0 or 1; b is 5 to 12; c is 0 or 1; S and T are independently sulfur, oxygen, or CH₂ with the proviso that S or T are not sulfur when p is 1 or 2; and B is C₁₋₄alkyl, ethynyl, trifluoromethyl, or phenyl optionally monosubstituted with Br, Cl, CF₃, C₁₋₄alkoxy, C₁₋₄alkyl, methylthio, or trifluoromethylthio; or 2) hydrogen, bromo, chloro, methyl, trifluoromethyl, methoxy or nitro; and A is selected from 2) as defined above or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament having LTB₄ antagonist activity.

  使用结构如下的化合物 其中 m 是 1 或 2；n 是 1、2 或 3；p 是 0、1 或 2；R′ 是氢或甲基；R 是被 A、R₁ 和 R₂ 取代的苯基，其中 R₁ 和 R₂ 独立选自 1) (S)a-(CH₂)b-(T)c-B 其中 a 是 0 或 1；(S)-(CH₂)b-(T)c-B 其中 a 是 0 或 1； b 是 5 至 12； c 是 0 或 1； S 和 T 独立地是硫、氧或 CH₂，但当 p 是 1 或 2 时，S 或 T 不是硫；B 是 C₁₋₄烷基、乙炔基、三氟甲基或苯基，可任选与 Br、Cl、CF₃、C₁₋₄烷氧基、C₁₋₄烷基、甲硫基或三氟甲基甲硫基单取代；或 2) 氢、溴、氯、甲基、三氟甲基、甲氧基或硝基；且 A 选自如上定义的 2) 或其药学上可接受的盐，用于制造具有 LTB₄ 拮抗剂活性的药物。
• Process for intermediates to leukotriene antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0295882B1

  公开（公告）日：1991-08-21
• Leukotriene antagonists
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0168902B1

  公开（公告）日：1987-09-30
• US4730005A
  申请人：——

  公开号：US4730005A

  公开（公告）日：1988-03-08
• US4777299A
  申请人：——

  公开号：US4777299A

  公开（公告）日：1988-10-11